SCHEDULE 13G: Octagon Capital Advisors and Affiliates Disclose 8.6% Passive Stake in Gossamer Bio

Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia have jointly reported a passive beneficial ownership of 8.6% in Gossamer Bio, Inc.'s common stock as of December 31, 2024.

Summary

• The filing identifies Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia as the Reporting Persons.
• The Issuer is Gossamer Bio, Inc., a company with its principal executive offices in San Diego, California.
• The Reporting Persons collectively beneficially own 19,576,054 shares of Gossamer Bio, Inc. Common Stock.
• This ownership represents 8.6% of the total class of securities.
• The beneficial ownership includes 18,350,000 directly held Common Shares and warrants to purchase an additional 1,226,054 Common Shares.
• The warrants have an exercise price of $2.04 per Common Share and are set to expire on July 24, 2028.
• The percentage of class was calculated based on 226,604,137 Common Shares outstanding as of November 4, 2024, as reported by Gossamer Bio, Inc. in its Form 10-Q filed on November 7, 2024, plus the shares issuable from the warrants.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G) indicating a passive stake. It contains no positive or negative operational or financial news about the issuer, Gossamer Bio, Inc. The sentiment is neutral as it simply reports a factual ownership position.

Positives

• A significant institutional investor, Octagon Capital Advisors LP, and its affiliates hold a substantial stake, indicating a vote of confidence in Gossamer Bio, Inc.
• The holding is classified as passive, suggesting no immediate intent to disrupt company operations or management, which can provide stability.

Negatives

• The document does not present any negative financial or operational information about Gossamer Bio, Inc., as it is a beneficial ownership report focused solely on ownership disclosure.

Risks

• The document itself does not detail risks related to Gossamer Bio, Inc.'s operations or financial health. However, a potential risk related to the reported ownership is that the warrants to purchase 1,226,054 Common Shares may expire unexercised if Gossamer Bio's stock price does not exceed the $2.04 exercise price by the July 24, 2028 expiration date.

Future Outlook

The document is a beneficial ownership report and does not provide forward-looking statements or guidance regarding Gossamer Bio, Inc.'s future performance, strategic outlook, or operational plans. It solely details the current ownership stake of the reporting entities.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing indicates a significant passive investment by Octagon Capital Advisors and its affiliates in Gossamer Bio, Inc., a biotechnology company. Such filings are routine disclosures for investors holding more than 5% of a company's stock and typically reflect a long-term, passive investment strategy rather than an active attempt to influence corporate strategy. The presence of institutional investors like Octagon is common across the biotechnology sector, where capital-intensive research and development often attract specialized funds.

Comparison to Industry Standards

• This document is a standard beneficial ownership disclosure (Schedule 13G) and does not contain financial or operational results of Gossamer Bio, Inc. that would allow for a direct comparison to industry standards or specific comparable companies/projects.
• The filing solely details the ownership stake of Octagon Capital Advisors LP and its affiliates, which is a common practice for institutional investors exceeding the 5% ownership threshold in publicly traded companies across various industries.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's passive stake, which can be viewed as a vote of confidence in the company's long-term prospects.
• Management: The passive nature of the investment indicates no immediate intent from the Reporting Persons to influence or challenge current management or strategic direction.

Next Steps

• The Reporting Persons will be required to file amendments to this Schedule 13G if there are material changes to their beneficial ownership (e.g., crossing a 1% threshold up or down) or an annual amendment by February 14th of each year to report their holdings as of December 31st.

Key Dates

Keywords

Gossamer Bio, Octagon Capital Advisors, Octagon Investments Master Fund, Ting Jia, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment Management, Passive Investment, Warrants